AbbVie

Open: 179.84 Close: 177.88 Change: -1.96

What an AI found about AbbVie Stock after reading the whole Internet.

This document will help you to evaluate AbbVie without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, change, site, market, Abbvie, month, link, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

For the current quarter, Abbvie is expected to post earnings of $2.34 per share, indicating a change of -4.9% from the year-ago quarter. For next fiscal year, the consensus earnings estimate of $12.20 indicates a change.

Today's News

AbbVies Produodopa approved by SMC to treat Parkinsons disease patients in Scotland. The progressive neurological disorder affects approximately 12,400 people. AbbVie is selling around $15 billion of bonds in the US investment-grade market to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics Holdings. The drugmakers founding CEO Richard Gonzalez will step down July 1. AbbVie (ABBV) is a Trending Stock. For the current quarter, Abbvie is expected to post earnings of $2.34 per share, indicating a change of -4.9% from the year-ago quarter. For next fiscal year, the consensus earnings estimate of $12.20 indicates a change. of +9.3% from what Abb If you are having difficulty paying for your medicine, AbbVie may be able to help. US-HUM-230194 Leaving Abbvie Web Site You are leaving the site and connecting to a site that is not under the control of AbbVsie.com. Overall spend dropped month over month, though this is a typical change for the time of year. Rinvoq claimed the top spot last month, surpassing its fellow immunology blockbuster Skyrizi. AbbVie is not responsible for the contents of any such site or any further links from such site. The presence of this link does not imply the linked sites endorsement of HUMIRA.com or Abbvie.com. The next AbbBVie (ABBV) dividend date is projected to be Friday, April 12. AbbVie, Inc. Last Close: 177.88 Dollar change -3.32 Percentage change -1.83% AbbVie is seeking a highly motivated scientist with a proven track record in biologics drug product development to serve as a principal research scientist in the Bio DPD group in Lake County. The Biologics Drug Product Development (Bio DPD) is a global organization within Abbvie. AbbVie (abbv) dipped more than broader market today. why abbvie (Abvie) dipped. More than Broader Market Today. why Abbvies dipped more Than broader market.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

How much time have you spent trying to decide whether investing in AbbVie? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, change, site, market, Abbvie, month, link, and the most common words in the summary are: abbvie, stock, job, market, get, direction, abbv, . One of the sentences in the summary was: For the current quarter, Abbvie is expected to post earnings of $2.34 per share, indicating a change of -4.9% from the year-ago quarter. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #stock #job #market #get #direction #abbv.